Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445455 | 0.82 | TRPV4 (0.57) | TRPV4SLC22A12IDO1SRCMAOA | |
| SCHEMBL769392 | 0.78 | MAOB (0.42) | TRPV4MAPK1MAOAMAOB | |
| SCHEMBL2490883 | 0.77 | MAPK1 (0.38) | VCAM1IDO1MAPK1 | |
| SCHEMBL104941 | 0.76 | VCAM1 (0.52) | VCAM1TRPV4SLC22A12IDO1GRM4 | |
| SCHEMBL1914246 | 0.76 | GRM4 (0.38) | TRPV4GRM4DYRK1A | |
| SCHEMBL22022696 | 0.75 | AR (0.44) | — | |
| SCHEMBL29898505 | 0.74 | VCAM1 (0.50) | VCAM1TRPV4SLC22A12IDO1GRM4 | |
| Fluoride SCHEMBL27571082 | 0.74 | VCAM1 (0.50) | VCAM1TRPV4SLC22A12IDO1GRM4 | |
| SCHEMBL3838602 | 0.74 | VCAM1 (0.50) | VCAM1TRPV4SLC22A12IDO1GRM4 | |
| SCHEMBL25179564 | 0.73 | TRPV4 (0.38) | VCAM1TRPV4SRCMAPK1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340982-B1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3340982-B1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3340982-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | NOVARTIS AG (CH) | 2018-01-04 | — | — | US | disclosed |
| WO-2017035408-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| CN-101460505-A | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INT (DE) | 2009-06-17 | — | — | CN | disclosed |
| EP-2018385-A1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008100618-A2 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007115929-A1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | VCAM1 4768/4885TRPV4 2578/4885SLC22A12 3904/4885 |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | CFD, TFPI, CFH | VCAM1 119/4885TRPV4 4376/4885SLC22A12 3982/4885 |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | WNT1, CTNNB1, CTNNA1 | VCAM1 4559/4885TRPV4 1807/4885SLC22A12 2396/4885 |
| US-20180000832-A1 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, CTNNA1 | VCAM1 4559/4885TRPV4 1807/4885SLC22A12 2396/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | VCAM1 1019/4885TRPV4 387/4885SLC22A12 3946/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | VCAM1 4842/4885TRPV4 2508/4885SLC22A12 3121/4885 |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | CFD, TFPI, CFH | VCAM1 119/4885TRPV4 4376/4885SLC22A12 3982/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | VCAM1 4669/4885TRPV4 1659/4885SLC22A12 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.